Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to find out if tocilizumab can be safely infused into chest or
abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions
(MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will
be greater than the previous one.
Phase:
Phase 1
Details
Lead Sponsor:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)